Liver Cancer - Pipeline Review, H2 2016

 

Rating

4.9 Star Rating for report Liver Cancer - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 1171
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.

Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC9101IDBLeiomyosarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9094IDBB-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9143IDBMalignant Mesothelioma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9103IDBSynovial Sarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9099IDBRectal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9098IDBAnal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9141IDBHepatic - Colorectal Metastasis - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9138IDBCancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9142IDBHypopharyngeal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9102IDBFibrosarcoma - Pipeline Review, H1 2017Mar 2017

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-30 

Report: Liver Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 10
Liver Cancer Overview 11
Therapeutics Development 12
Liver Cancer - Therapeutics under Development by Companies 14
Liver Cancer - Therapeutics under Investigation by Universities/Institutes 29
Liver Cancer - Pipeline Products Glance 32
Liver Cancer - Products under Development by Companies 35
Liver Cancer - Products under Investigation by Universities/Institutes 56
Liver Cancer - Companies Involved in Therapeutics Development 60
Liver Cancer - Therapeutics Assessment 245
Drug Profiles 277
Liver Cancer - Dormant Projects 1096
Liver Cancer - Discontinued Products 1116
Liver Cancer - Product Development Milestones 1120
Appendix 1133
 

List of Tables

List of Tables
Number of Products under Development for Liver Cancer, H2 2016 49
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016 50
Number of Products under Development by Companies, H2 2016 51
Number of Products under Development by Companies, H2 2016 (Contd..1) 52
Number of Products under Development by Companies, H2 2016 (Contd..2) 53
Number of Products under Development by Companies, H2 2016 (Contd..3) 54
Number of Products under Development by Companies, H2 2016 (Contd..4) 55
Number of Products under Development by Companies, H2 2016 (Contd..5) 56
Number of Products under Development by Companies, H2 2016 (Contd..6) 57
Number of Products under Development by Companies, H2 2016 (Contd..7) 58
Number of Products under Development by Companies, H2 2016 (Contd..8) 59
Number of Products under Development by Companies, H2 2016 (Contd..9) 60
Number of Products under Development by Companies, H2 2016 (Contd..10) 61
Number of Products under Development by Companies, H2 2016 (Contd..11) 62
Number of Products under Development by Companies, H2 2016 (Contd..12) 63
Number of Products under Development by Companies, H2 2016 (Contd..13) 64
Number of Products under Development by Companies, H2 2016 (Contd..14) 65
Number of Products under Investigation by Universities/Institutes, H2 2016 66
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 67
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 68
Comparative Analysis by Late Stage Development, H2 2016 69
Comparative Analysis by Clinical Stage Development, H2 2016 70
Comparative Analysis by Early Stage Development, H2 2016 71
Products under Development by Companies, H2 2016 72
Products under Development by Companies, H2 2016 (Contd..1) 73
Products under Development by Companies, H2 2016 (Contd..2) 74
Products under Development by Companies, H2 2016 (Contd..3) 75
Products under Development by Companies, H2 2016 (Contd..4) 76
Products under Development by Companies, H2 2016 (Contd..5) 77
Products under Development by Companies, H2 2016 (Contd..6) 78
Products under Development by Companies, H2 2016 (Contd..7) 79
Products under Development by Companies, H2 2016 (Contd..8) 80
Products under Development by Companies, H2 2016 (Contd..9) 81
Products under Development by Companies, H2 2016 (Contd..10) 82
Products under Development by Companies, H2 2016 (Contd..11) 83
Products under Development by Companies, H2 2016 (Contd..12) 84
Products under Development by Companies, H2 2016 (Contd..13) 85
Products under Development by Companies, H2 2016 (Contd..14) 86
Products under Development by Companies, H2 2016 (Contd..15) 87
Products under Development by Companies, H2 2016 (Contd..16) 88
Products under Development by Companies, H2 2016 (Contd..17) 89
Products under Development by Companies, H2 2016 (Contd..18) 90
Products under Development by Companies, H2 2016 (Contd..19) 91
Products under Development by Companies, H2 2016 (Contd..20) 92
Products under Investigation by Universities/Institutes, H2 2016 93
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 94
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 95
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 96
Liver Cancer - Pipeline by 4SC AG, H2 2016 97
Liver Cancer - Pipeline by AB Science SA, H2 2016 98
Liver Cancer - Pipeline by Acceleron Pharma Inc, H2 2016 99
Liver Cancer - Pipeline by ACROVIS Pharma AG, H2 2016 100
Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 101
Liver Cancer - Pipeline by Aduro BioTech Inc, H2 2016 102
Liver Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 103
Liver Cancer - Pipeline by Alfact Innovation, H2 2016 104
Liver Cancer - Pipeline by Alissa Pharma, H2 2016 105
Liver Cancer - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 106
Liver Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 107
Liver Cancer - Pipeline by Amgen Inc, H2 2016 108
Liver Cancer - Pipeline by AndroScience Corp, H2 2016 109
Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H2 2016 110
Liver Cancer - Pipeline by ArQule Inc, H2 2016 111
Liver Cancer - Pipeline by Array BioPharma Inc, H2 2016 112
Liver Cancer - Pipeline by Astellas Pharma Inc, H2 2016 113
Liver Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 114
Liver Cancer - Pipeline by AstraZeneca Plc, H2 2016 115
Liver Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 116
Liver Cancer - Pipeline by Bayer AG, H2 2016 117
Liver Cancer - Pipeline by BeiGene Ltd, H2 2016 118
Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 119
Liver Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 120
Liver Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 121
Liver Cancer - Pipeline by BioCancell Ltd, H2 2016 122
Liver Cancer - Pipeline by Biogazelle NV, H2 2016 123
Liver Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016 124
Liver Cancer - Pipeline by Bioneer Corp, H2 2016 125
Liver Cancer - Pipeline by BioStar Pharmaceuticals Inc, H2 2016 126
Liver Cancer - Pipeline by BLR Bio LLC, H2 2016 127
Liver Cancer - Pipeline by Blueprint Medicines Corp, H2 2016 128
Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 129
Liver Cancer - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 130
Liver Cancer - Pipeline by Boston Biomedical Inc, H2 2016 131
Liver Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 132
Liver Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016 133
Liver Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 134
Liver Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016 135
Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016 136
Liver Cancer - Pipeline by Celgene Corp, H2 2016 137
Liver Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 138
Liver Cancer - Pipeline by Celprogen Inc, H2 2016 139
Liver Cancer - Pipeline by Celsion Corp, H2 2016 140
Liver Cancer - Pipeline by China Medical System Holdings Ltd, H2 2016 141
Liver Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 142
Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 143
Liver Cancer - Pipeline by Chroma Therapeutics Ltd, H2 2016 144
Liver Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 145
Liver Cancer - Pipeline by CohBar Inc, H2 2016 146
Liver Cancer - Pipeline by CZ BioMed Corp, H2 2016 147
Liver Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 148
Liver Cancer - Pipeline by Delcath Systems Inc, H2 2016 149
Liver Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 150
Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 151
Liver Cancer - Pipeline by Eisai Co Ltd, H2 2016 152
Liver Cancer - Pipeline by Eli Lilly and Company, H2 2016 153
Liver Cancer - Pipeline by Endocyte Inc, H2 2016 154
Liver Cancer - Pipeline by Epeius Biotechnologies Corp, H2 2016 155
Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H2 2016 156
Liver Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016 157
Liver Cancer - Pipeline by Exelixis Inc, H2 2016 158
Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 159
Liver Cancer - Pipeline by Faron Pharmaceuticals Oy, H2 2016 160
Liver Cancer - Pipeline by Formosa Laboratories Inc, H2 2016 161
Liver Cancer - Pipeline by Galaxy Biotech LLC, H2 2016 162
Liver Cancer - Pipeline by Genelux Corp, H2 2016 163
Liver Cancer - Pipeline by Genoscience Pharma, H2 2016 164
Liver Cancer - Pipeline by Genosco Inc, H2 2016 165
Liver Cancer - Pipeline by Gilead Sciences Inc, H2 2016 166
Liver Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 167
Liver Cancer - Pipeline by Golden Biotechnology Corp, H2 2016 168
Liver Cancer - Pipeline by Green Cross Cell Corp, H2 2016 169
Liver Cancer - Pipeline by Green Cross Corp, H2 2016 170
Liver Cancer - Pipeline by H3 Biomedicine Inc, H2 2016 171
Liver Cancer - Pipeline by HanAll Biopharma Co Ltd, H2 2016 172
Liver Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016 173
Liver Cancer - Pipeline by HitGen LTD, H2 2016 174
Liver Cancer - Pipeline by Horizon Pharma Plc, H2 2016 175
Liver Cancer - Pipeline by Immune Therapeutics Inc, H2 2016 176
Liver Cancer - Pipeline by Immunicum AB, H2 2016 177
Liver Cancer - Pipeline by Immunitor Inc, H2 2016 178
Liver Cancer - Pipeline by Immunomedics Inc, H2 2016 179
Liver Cancer - Pipeline by Immunophotonics Inc, H2 2016 180
Liver Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016 181
Liver Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016 182
Liver Cancer - Pipeline by In-Cell-Art SAS, H2 2016 183
Liver Cancer - Pipeline by Incanthera Ltd, H2 2016 184
Liver Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 185
Liver Cancer - Pipeline by Inspyr Therapeutics Inc, H2 2016 186
Liver Cancer - Pipeline by InteRNA Technologies BV, H2 2016 187
Liver Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 188
Liver Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 189
Liver Cancer - Pipeline by Jenrin Discovery Inc, H2 2016 190
Liver Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 191
Liver Cancer - Pipeline by Johnson & Johnson, H2 2016 192
Liver Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016 193
Liver Cancer - Pipeline by KAHR medical Ltd, H2 2016 194
Liver Cancer - Pipeline by Karcinolys SAS, H2 2016 195
Liver Cancer - Pipeline by Keystone Nano Inc, H2 2016 196
Liver Cancer - Pipeline by Kite Pharma Inc, H2 2016 197
Liver Cancer - Pipeline by Komipharm International Co Ltd, H2 2016 198
Liver Cancer - Pipeline by Kowa Company Ltd, H2 2016 199
Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016 200
Liver Cancer - Pipeline by Lidds AB, H2 2016 201
Liver Cancer - Pipeline by Ligand Pharmaceuticals Inc, H2 2016 202
Liver Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 203
Liver Cancer - Pipeline by Lytix Biopharma AS, H2 2016 204
Liver Cancer - Pipeline by MaxCyte Inc, H2 2016 205
Liver Cancer - Pipeline by MedImmune LLC, H2 2016 206
Liver Cancer - Pipeline by Medivation Inc, H2 2016 207
Liver Cancer - Pipeline by Medivir AB, H2 2016 208
Liver Cancer - Pipeline by Merck & Co Inc, H2 2016 209
Liver Cancer - Pipeline by Merck KGaA, H2 2016 210
Liver Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 211
Liver Cancer - Pipeline by Midatech Pharma Plc, H2 2016 212
Liver Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 213
Liver Cancer - Pipeline by Mina Therapeutics Ltd, H2 2016 214
Liver Cancer - Pipeline by Molecular Partners AG, H2 2016 215
Liver Cancer - Pipeline by MultiCell Technologies Inc, H2 2016 216
Liver Cancer - Pipeline by NormOxys Inc, H2 2016 217
Liver Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 218
Liver Cancer - Pipeline by Novartis AG, H2 2016 219
Liver Cancer - Pipeline by NovaTarg Therapeutics Inc, H2 2016 220
Liver Cancer - Pipeline by Nymox Pharmaceutical Corp, H2 2016 221
Liver Cancer - Pipeline by Omeros Corp, H2 2016 222
Liver Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 223
Liver Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016 224
Liver Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 225
Liver Cancer - Pipeline by OncoTherapy Science Inc, H2 2016 226
Liver Cancer - Pipeline by Oneness Biotech Co Ltd, H2 2016 227
Liver Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 228
Liver Cancer - Pipeline by Onxeo SA, H2 2016 229
Liver Cancer - Pipeline by OPKO Health Inc, H2 2016 230
Liver Cancer - Pipeline by Oribase Pharma, H2 2016 231
Liver Cancer - Pipeline by OSE Immunotherapeutics, H2 2016 232
Liver Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2016 233
Liver Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 234
Liver Cancer - Pipeline by Peptinov SAS, H2 2016 235
Liver Cancer - Pipeline by PepVax Inc, H2 2016 236
Liver Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016 237
Liver Cancer - Pipeline by Pfizer Inc, H2 2016 238
Liver Cancer - Pipeline by Pharma Mar SA, H2 2016 239
Liver Cancer - Pipeline by PharmAbcine Inc, H2 2016 240
Liver Cancer - Pipeline by PharmaEssentia Corp, H2 2016 241
Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2016 242
Liver Cancer - Pipeline by ProMetic Life Sciences Inc, H2 2016 243
Liver Cancer - Pipeline by Provecs Medical GmbH, H2 2016 244
Liver Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 245
Liver Cancer - Pipeline by RedHill Biopharma Ltd, H2 2016 246
Liver Cancer - Pipeline by Regen BioPharma Inc, H2 2016 247
Liver Cancer - Pipeline by Regulus Therapeutics Inc, H2 2016 248
Liver Cancer - Pipeline by Rigontec GmbH, H2 2016 249
Liver Cancer - Pipeline by Samumed LLC, H2 2016 250
Liver Cancer - Pipeline by Saronic Biotechnology Inc, H2 2016 251
Liver Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016 252
Liver Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2016 253
Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2016 254
Liver Cancer - Pipeline by Silence Therapeutics Plc, H2 2016 255
Liver Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016 256
Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016 257
Liver Cancer - Pipeline by Somantix BV, H2 2016 258
Liver Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 259
Liver Cancer - Pipeline by Synovo GmbH, H2 2016 260
Liver Cancer - Pipeline by TaiRx Inc, H2 2016 261
Liver Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016 262
Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 263
Liver Cancer - Pipeline by Targetome SA, H2 2016 264
Liver Cancer - Pipeline by TC BioPharm Ltd, H2 2016 265
Liver Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 266
Liver Cancer - Pipeline by Therapure Biopharma Inc, H2 2016 267
Liver Cancer - Pipeline by Theravectys SA, H2 2016 268
Liver Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 269
Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2016 270
Liver Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 271
Liver Cancer - Pipeline by Transgene Biotek Ltd, H2 2016 272
Liver Cancer - Pipeline by Tumorend LLC, H2 2016 273
Liver Cancer - Pipeline by UbiVac LLC, H2 2016 274
Liver Cancer - Pipeline by VasGene Therapeutics Inc, H2 2016 275
Liver Cancer - Pipeline by Vaxon Biotech, H2 2016 276
Liver Cancer - Pipeline by Vect-Horus SAS, H2 2016 277
Liver Cancer - Pipeline by Verlyx Pharma Inc, H2 2016 278
Liver Cancer - Pipeline by VG Life Sciences Inc, H2 2016 279
Liver Cancer - Pipeline by Vicus Therapeutics LLC, H2 2016 280
Liver Cancer - Pipeline by Virttu Biologics Ltd, H2 2016 281
Assessment by Monotherapy Products, H2 2016 282
Assessment by Combination Products, H2 2016 283
Number of Products by Stage and Target, H2 2016 285
Number of Products by Stage and Mechanism of Action, H2 2016 298
Number of Products by Stage and Route of Administration, H2 2016 311
Number of Products by Stage and Molecule Type, H2 2016 313
Liver Cancer - Dormant Projects, H2 2016 1133
Liver Cancer - Dormant Projects (Contd..1), H2 2016 1134
Liver Cancer - Dormant Projects (Contd..2), H2 2016 1135
Liver Cancer - Dormant Projects (Contd..3), H2 2016 1136
Liver Cancer - Dormant Projects (Contd..4), H2 2016 1137
Liver Cancer - Dormant Projects (Contd..5), H2 2016 1138
Liver Cancer - Dormant Projects (Contd..6), H2 2016 1139
Liver Cancer - Dormant Projects (Contd..7), H2 2016 1140
Liver Cancer - Dormant Projects (Contd..8), H2 2016 1141
Liver Cancer - Dormant Projects (Contd..9), H2 2016 1142
Liver Cancer - Dormant Projects (Contd..10), H2 2016 1143
Liver Cancer - Dormant Projects (Contd..11), H2 2016 1144
Liver Cancer - Dormant Projects (Contd..12), H2 2016 1145
Liver Cancer - Dormant Projects (Contd..13), H2 2016 1146
Liver Cancer - Dormant Projects (Contd..14), H2 2016 1147
Liver Cancer - Dormant Projects (Contd..15), H2 2016 1148
Liver Cancer - Dormant Projects (Contd..16), H2 2016 1149
Liver Cancer - Dormant Projects (Contd..17), H2 2016 1150
Liver Cancer - Dormant Projects (Contd..18), H2 2016 1151
Liver Cancer - Dormant Projects (Contd..19), H2 2016 1152
Liver Cancer - Discontinued Products, H2 2016 1153
Liver Cancer - Discontinued Products (Contd..1), H2 2016 1154
Liver Cancer - Discontinued Products (Contd..2), H2 2016 1155
Liver Cancer - Discontinued Products (Contd..3), H2 2016 1156
 

List of Figures

List of Figures
Number of Products under Development for Liver Cancer, H2 2016 49
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016 50
Number of Products under Development by Companies, H2 2016 51
Number of Products under Investigation by Universities/Institutes, H2 2016 66
Comparative Analysis by Late Stage Development, H2 2016 69
Comparative Analysis by Clinical Stage Development, H2 2016 70
Comparative Analysis by Early Stage Products, H2 2016 71
Assessment by Monotherapy Products, H2 2016 282
Assessment by Combination Products, H2 2016 283
Number of Products by Top 10 Targets, H2 2016 284
Number of Products by Stage and Top 10 Targets, H2 2016 284
Number of Products by Top 10 Mechanism of Actions, H2 2016 297
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 297
Number of Products by Top 10 Routes of Administration, H2 2016 310
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 310
Number of Products by Top 10 Molecule Types, H2 2016 312
Number of Products by Stage and Top 10 Molecule Types, H2 2016 312
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.

Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 1171 

Companies Featured

4SC AG AB Science SA Acceleron Pharma Inc ACROVIS Pharma AG Adaptimmune Therapeutics Plc Aduro BioTech Inc Advenchen Laboratories LLC Alfact Innovation Alissa Pharma Alnylam Pharmaceuticals Inc American Gene Technologies International Inc Amgen Inc AndroScience Corp APAvadis Biotechnologies Srl ArQule Inc Array BioPharma Inc Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Bayer AG BeiGene Ltd Beijing Kawin Technology Share-Holding Co Ltd Betta Pharmaceuticals Co Ltd Bio-Cancer Treatment International Ltd BioCancell Ltd Biogazelle NV Biomics Biotechnologies Co Ltd Bioneer Corp BioStar Pharmaceuticals Inc BLR Bio LLC Blueprint Medicines Corp Boehringer Ingelheim GmbH Boryung Pharmaceutical Co Ltd Boston Biomedical Inc Bristol-Myers Squibb Company Can-Fite BioPharma Ltd CASI Pharmaceuticals Inc CBT Pharmaceuticals Inc CCRP Therapeutics GmbH Celgene Corp Celldex Therapeutics Inc Celprogen Inc Celsion Corp China Medical System Holdings Ltd Chiome Bioscience Inc Chipscreen Biosciences Ltd Chroma Therapeutics Ltd Chugai Pharmaceutical Co Ltd CohBar Inc CZ BioMed Corp Daiichi Sankyo Company Ltd Delcath Systems Inc Dicerna Pharmaceuticals Inc Double Bond Pharmaceutical International AB Eisai Co Ltd Eli Lilly and Company Endocyte Inc Epeius Biotechnologies Corp eTheRNA Immunotherapies NV Eureka Therapeutics Inc Exelixis Inc F. Hoffmann-La Roche Ltd Faron Pharmaceuticals Oy Formosa Laboratories Inc Galaxy Biotech LLC Genelux Corp Genoscience Pharma Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Golden Biotechnology Corp Green Cross Cell Corp Green Cross Corp H3 Biomedicine Inc HanAll Biopharma Co Ltd HEC Pharm Co Ltd HitGen LTD Horizon Pharma Plc Immune Therapeutics Inc Immunicum AB Immunitor Inc Immunomedics Inc Immunophotonics Inc Immunovative Therapies Ltd IMPACT Therapeutics Inc In-Cell-Art SAS Incanthera Ltd Inovio Pharmaceuticals Inc Inspyr Therapeutics Inc InteRNA Technologies BV Intezyne Technologies Inc Jasco Pharmaceuticals LLC Jenrin Discovery Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson JW Pharmaceutical Corp KAHR medical Ltd Karcinolys SAS Keystone Nano Inc Kite Pharma Inc Komipharm International Co Ltd Kowa Company Ltd Les Laboratoires Servier SAS Lidds AB Ligand Pharmaceuticals Inc Lixte Biotechnology Holdings Inc Lytix Biopharma AS MaxCyte Inc MedImmune LLC Medivation Inc Medivir AB Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Midatech Pharma Plc Millennium Pharmaceuticals Inc Mina Therapeutics Ltd Molecular Partners AG MultiCell Technologies Inc NormOxys Inc Northwest Biotherapeutics Inc Novartis AG NovaTarg Therapeutics Inc Nymox Pharmaceutical Corp Omeros Corp Omnitura Therapeutics Inc Oncolys BioPharma Inc OncoMed Pharmaceuticals Inc OncoTherapy Science Inc Oneness Biotech Co Ltd Ono Pharmaceutical Co Ltd Onxeo SA OPKO Health Inc Oribase Pharma OSE Immunotherapeutics Otsuka Holdings Co Ltd Panacea Pharmaceuticals Inc Peptinov SAS PepVax Inc Peregrine Pharmaceuticals Inc Pfizer Inc Pharma Mar SA PharmAbcine Inc PharmaEssentia Corp Phosplatin Therapeutics LLC ProMetic Life Sciences Inc Provecs Medical GmbH Provectus Biopharmaceuticals Inc RedHill Biopharma Ltd Regen BioPharma Inc Regulus Therapeutics Inc Rigontec GmbH Samumed LLC Saronic Biotechnology Inc Savoy Pharmaceuticals Inc Shenogen Pharma Group Ltd Shenzen SiBiono GeneTech Co Ltd Silence Therapeutics Plc Sillajen Biotherapeutics Simcere Pharmaceutical Group Somantix BV Sorrento Therapeutics Inc Synovo GmbH TaiRx Inc Taiwan Liposome Company Ltd Tara Immuno-Oncology Therapeutics LLC Targetome SA TC BioPharm Ltd Tessa Therapeutics Pte Ltd Therapure Biopharma Inc Theravectys SA Threshold Pharmaceuticals Inc Tiziana Life Sciences Plc TRACON Pharmaceuticals Inc Transgene Biotek Ltd Tumorend LLC UbiVac LLC VasGene Therapeutics Inc Vaxon Biotech Vect-Horus SAS Verlyx Pharma Inc VG Life Sciences Inc Vicus Therapeutics LLC Virttu Biologics Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC9101IDBLeiomyosarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9094IDBB-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9143IDBMalignant Mesothelioma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9103IDBSynovial Sarcoma - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9099IDBRectal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9098IDBAnal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9141IDBHepatic - Colorectal Metastasis - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9138IDBCancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9142IDBHypopharyngeal Cancer - Pipeline Review, H1 2017Mar 2017
Report... 05IB-GMDHC9102IDBFibrosarcoma - Pipeline Review, H1 2017Mar 2017

Liver Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8854IDB has a rating of 97 percent
Figure of merit assessment for report 05IB-GMDHC8854IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Liver Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8854IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.46849s]

--